1,3,5-Tribromo-2-(prop-2-en-1-yloxy)benzene
Associated AOPs with Level of Relevance - 1 AOPs with at least 1 KE associated with chemical, where the KE(s) are neither MIE nor AO
| AOP Identifier |
AOP Title |
AO Classification |
OECD Status |
Taxonomic applicability |
Coverage Score
ⓘ
The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints.
|
KE Identifier |
KE Name |
| AOP:414 | Aryl hydrocarbon receptor activation leading to lung fibrosis through TGF-β dependent fibrosis toxicity pathway | Musculoskeletal system disease; Respiratory system disease | - | | 0.2 | KE:1920 | Altered gene expression, TGF-β dependent fibrosis pathway |
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | | 0.12 | KE:1987 | Decreased, Androgen and Progestin |
No associated AOPs with Level of Relevance 2
Associated AOPs with Level of Relevance - 3 AOPs with at least 1 MIE associated with chemical, and no associated AO
| AOP Identifier |
AOP Title |
AO Classification |
OECD Status |
Taxonomic applicability |
Coverage Score
ⓘ
The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints.
|
KE Identifier |
KE Name |
| AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | Humans | 0.2 | KE:1866 | Fibrinolysis, decreased |
| AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental disorder of mental health | - | Mouse, Rat, Human | 0.2 | KE:2201 | Agonism, Retinoic acid receptor |
| AOP:523 | Retinoic acid receptor agonism during neurodevelopment leading to microcephaly | Congenital nervous system abnormality; Nervous system disease | - | | 0.2 | KE:2201 | Agonism, Retinoic acid receptor |
| AOP:532 | Retinoic acid receptor agonism during cerebellar development leading to impaired locomotor function | Unclassified | - | | 0.2 | KE:2201 | Agonism, Retinoic acid receptor |
No associated AOPs with Level of Relevance 5
DISCLAIMER
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.